The rational use of diuretics in heart failure

[1]  R. Califf,et al.  Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) , 2002, Circulation.

[2]  Nancee V. Niemeyer,et al.  Thiazolidinedione‐Induced Edema , 2002, Pharmacotherapy.

[3]  S. Su,et al.  Effect of Pravastatin on Proteinuria in Patients With Well-Controlled Hypertension , 2002, Hypertension.

[4]  C. O'connor,et al.  Diuretic resistance predicts mortality in patients with advanced heart failure. , 2002, American heart journal.

[5]  R. Harris,et al.  Cyclooxygenase-2 inhibition and renal physiology. , 2002, The American journal of cardiology.

[6]  S. Gottlieb,et al.  BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy , 2002, Circulation.

[7]  J. Ghali,et al.  Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .

[8]  F. Ruschitzka,et al.  Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? , 2001, Journal of the American College of Cardiology.

[9]  M. Dunn,et al.  Aggressive diuresis for severe heart failure in the elderly. , 2001, Chest.

[10]  G. Fonarow,et al.  Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. , 2000, American heart journal.

[11]  M. Pfeffer,et al.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial , 2000, The Lancet.

[12]  A. Charlesworth,et al.  Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.

[13]  H. Krumholz,et al.  Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. , 2000, The American journal of cardiology.

[14]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[15]  Thomas D. Giles,et al.  Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .

[16]  P. Hunziker,et al.  Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. , 1998, Circulation.

[17]  U. Elkayam,et al.  Renal circulatory effects of adenosine in patients with chronic heart failure. , 1998, Journal of the American College of Cardiology.

[18]  D. Fukai,et al.  Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. , 1997, Journal of the American College of Cardiology.

[19]  J. Gorski,et al.  Role of duration of diuretic effect in preventing sodium retention , 1997, Clinical pharmacology and therapeutics.

[20]  E. Mutschler,et al.  Sequential nephron blockade breaks resistance to diuretics in edematous states. , 1997, Journal of cardiovascular pharmacology.

[21]  M. Dunn,et al.  Severe musculoskeletal symptoms during continuous infusion of bumetanide. , 1997, Chest.

[22]  E. Mutschler,et al.  Diuretic Effectiveness of Hydrochlorothiazide and Furosemide Alone and in Combination in Chronic Renal Failure , 1995, Journal of cardiovascular pharmacology.

[23]  H. Nogami,et al.  Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1. , 1995, Kidney international.

[24]  L. Danziger,et al.  Continuous infusion of loop diuretics in the critically ill: A review of the literature , 1994, Critical care medicine.

[25]  E. Mutschler,et al.  Functional state of the nephron and diuretic dose-response--rationale for low-dose combination therapy. , 1994, Cardiology.

[26]  F. Russel,et al.  Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance , 1994, Journal of internal medicine.

[27]  K. Channer,et al.  Combination diuretic treatment in severe heart failure: a randomised controlled trial. , 1994, British heart journal.

[28]  R. Cody.  Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. , 1993, Journal of the American College of Cardiology.

[29]  W. Abraham,et al.  Edematous disorders: pathophysiology of renal sodium and water retention and treatment with diuretics. , 1993, Current opinion in nephrology and hypertension.

[30]  M. Lahav,et al.  Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. , 1992, Chest.

[31]  D. Ellison.  The physiologic basis of diuretic synergism: its role in treating diuretic resistance. , 1991, Annals of internal medicine.

[32]  R. Unwin,et al.  Mechanism of impaired natriuretic response to furosemide during prolonged therapy. , 1989, Kidney international.

[33]  D. Brater,et al.  Response to furosemide in chronic renal insufficiency: Rationale for limited doses , 1986, Clinical pharmacology and therapeutics.

[34]  J. Mackenzie,et al.  Postoperative enhancement of urinary output in patients with acute renal failure using continuous furosemide therapy. , 1986, Chest.

[35]  M. Epstein,et al.  Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. , 1983, Annals of internal medicine.

[36]  R. Tarazi,et al.  Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. , 1982, The American journal of medicine.

[37]  L. Tavazzi,et al.  Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). , 2002, American heart journal.

[38]  W. Abraham,et al.  Pathophysiology and clinical spectrum of acute congestive heart failure. , 2001, Reviews in cardiovascular medicine.

[39]  M. Creager.  Beta-blockers for vascular surgery and angioplasty for renal artery stenosis. , 2001, Reviews in cardiovascular medicine.

[40]  M. Fisher,et al.  Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.